Weekly Intelligence Digest — 18–24 May 2026

FDA draft guidance tightens safety expectations for human gene-editing therapies, raising the bar for AI-driven off-target analysis

FDA CBER issued draft guidance in April 2026 — "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing" — that explicitly expects sponsors to use NGS-based methods to characterize off-target edits and chromosomal integrity. Comments are due by July 14, 2026. The guidance applies to CRISPR, base-editing, and prime-editing platforms, and covers both ex vivo and in vivo products.

Why it matters: Sponsors using AI/ML for off-target prediction and NGS analytics now face explicit regulatory expectations for auditable, validated bioinformatics pipelines. If your gene-editing IND still treats bioinformatics as a post-hoc QC step rather than a pre-specified component of the safety package, this guidance is your wake-up call.

FDA genome-editing guidance formalizes NGS and bioinformatics expectations across editing platforms

The April 2026 draft guidance pushes sponsors toward more sophisticated NGS and bioinformatics strategies to quantify off-target edits and structural variants. It also signals that even small rare-disease trials will need statistically robust evidence that observed benefits are not chance artifacts from editing-related genomic disruption.

Why it matters: Together with the February 2026 plausible mechanism pathway draft, this guidance begins to define a more coherent regulatory architecture for personalized and bespoke gene therapies. Teams with gene-editing programs should consider formal comments to CBER before the July 14 deadline.

Novartis tees up a radioligand flex at ASCO and EHA with new Pluvicto data and early actinium-based RLT

On May 21, 2026, Novartis previewed its ASCO and EHA 2026 slate: more than 65 company- or investigator-sponsored abstracts, including a Pluvicto PSMAddition oral presentation highlighting efficacy by disease volume and de novo/recurrent mHSPC status, Kisqali NATALEE biomarker data, longer-term Scemblix 144-week results, Phase 3 ianalumab in ITP, and — notably — early Phase 1 data from an actinium-based radioligand therapy program.

Why it matters: The actinium-RLT entry is the strategic headline beneath the headline. It signals that Novartis is already building the next-generation alpha-emitter pipeline while Pluvicto is still expanding into earlier prostate cancer settings. This is the industrial-scale version of RLT as a platform, not a single-asset curiosity.

Pluvicto PSMAddition shows 58% lower risk of PSA progression in mHSPC

A May 17, 2026 Novartis press release reported that Pluvicto plus standard of care (ARPI + ADT) delivered a 58% lower risk of PSA progression versus standard of care alone in metastatic hormone-sensitive prostate cancer, with deeper and more durable PSA responses at 12 months.

Why it matters: PSMAddition data continue to strengthen the case for moving Pluvicto into the earliest metastatic setting. FDA submission remains targeted for H2 2026, and the PSA data provide additional ammunition for the regulatory package.

Real-world and pooled ORION data confirm sustained ~50% LDL-C reductions with twice-yearly inclisiran

A February 2025 review in Frontiers in Pharmacology consolidated clinical trial and real-world evidence for inclisiran, confirming time-averaged LDL-C reductions of approximately 50% with a safety profile comparable to placebo and durable twice-yearly dosing. The review covers ORION-9/10/11 and emerging real-world datasets.

Why it matters: Inclisiran remains the reference siRNA PCSK9 agent. Any next-gen lipid-lowering modality — oral PCSK9s, gene editing, or alternative siRNA designs — will be benchmarked against this durability and safety profile. The unresolved question remains cardiovascular hard outcomes from ORION-4, expected in 2026.

Inclisiran label evolution from high-risk adjunct to broader LDL-C management workhorse

FDA initially approved inclisiran (Leqvio) in December 2021 as an siRNA adjunct to maximally tolerated statin therapy in ASCVD/HeFH. The label has since expanded progressively to include primary hyperlipidemia and, by 2025, first-line monotherapy options.

Why it matters: This label expansion playbook — from narrow high-risk adjunct to broad primary prevention — is now the path that PCSK9-targeting competitors must beat on both LDL-C durability and cardiovascular outcomes.

Mark Rutstein, MD, Global Head of Oncology Development, Novartis

In the May 21 ASCO/EHA preview, Rutstein positioned the actinium-based RLT as an early pipeline signal within a broader RLT platform: "We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT."

Why it matters: This is not a routine conference preview. It is the public-facing confirmation that large sponsors now treat radioligand platforms as core oncology franchises that must be resourced like immuno-oncology — with parallel investments in alpha emitters, beta emitters, manufacturing, and companion imaging — not as boutique nuclear medicine side projects.

Novartis RLT manufacturing expansion continues alongside Pluvicto regulatory activity

Novartis has continued to expand its US RLT manufacturing footprint through early 2026, including new sites in Texas and Florida, while managing the European regulatory landscape for Pluvicto. This dual-track approach — manufacturing scale-up plus regulatory navigation — has become the RLT industry playbook.

Why still relevant: For any sponsor entering the RLT space, the Novartis template is now clear: synchronize clinical strategy, CMC scale-up, and supply resilience from the start. "Supply constraints" is not a slide you want to present on an investor call.

Inclisiran ORION-4 outcomes data remain the pivotal watch item for cardiovascular field

While real-world and pooled Phase 3 data consistently show ~50% LDL-C reduction with inclisiran, the key unresolved question is whether this translates into cardiovascular hard outcome benefit. ORION-4 data, expected in 2026, could materially strengthen inclisiran's clinical and commercial position.

Why still relevant: A positive ORION-4 readout would reshape prevention logic beyond statins and could influence combination strategies with emerging PCSK9-targeted therapies including oral inhibitors and gene-editing approaches.

Regulatory: lock down AI and bioinformatics pipelines before your next gene-editing Type B meeting

Expect regulators to ask for transparent, explainable AI and bioinformatics pipelines in any gene-editing IND, with pre-specified plans for off-target and chromosomal-structure risk management. Version your tools, document your validation strategy, and submit comments to CBER before July 14, 2026.

RLT strategy: treat radioligand platforms like full-line oncology franchises

Align clinical strategy — earlier disease settings, combinations, hematology/breast expansion, alpha-emitter pipeline — with parallel investments in specialized manufacturing, supply resilience, and companion imaging infrastructure. The Novartis ASCO/EHA slate is the benchmark.

Lipids competitive intelligence: "non-inferior but cooler mechanism" will not cut it

The competitive landscape around inclisiran means any siRNA or gene-editing PCSK9 challenger needs a clearly superior composite of LDL-C reduction, dosing convenience, outcomes data, and payer-friendly implementation. For trial design, comparator-arm assumptions and background therapy definitions should account for Lerochol's commercial presence, enlicitide's oral convenience, and pelacarsen's Lp(a)-specific positioning.

Open-source medical AI: start with low-regret use cases and build a validation blueprint

Open-source medical AI stacks are moving from sandbox to regulated pilots. Clinical development teams should start with low-regret use cases — site selection, query management, safety signal triage — and build a validation and monitoring blueprint that statisticians and regulators will take seriously.

RLT trial design: harmonize with Pluvicto-era benchmarks

For radioligand theranostics programs, harmonize trial design with evolving RLT real-world data and upcoming ASCO/EHA readouts. Assume future protocols will be judged against Pluvicto-era benchmarks for survival, quality of life, and manufacturing reliability — not against yesterday's chemo comparators.